Drogas anorexígenas en el tratamiento de la obesidad / Anorexigenic drugs in the treatment of obesity
Rev. méd. Chile
; 123(5): 637-40, mayo 1995.
Article
en Es
| LILACS
| ID: lil-152868
Biblioteca responsable:
CL1.1
RESUMO
Obesity is highly prevalent and has several adverse effects on health. Its treatment is thus warranted and must aim to modify dietary and physical activity habits. The opinion of this association is that anorexigenic drugs with cathecolaminergic action (diethylpropion, phentermine, mazindol and phenylpropanolamine) or serotoninergic action (fenfluoramine and fluoxetine) may be used in moderate or severe obesity (BMI >30 kg/m2) after a complete clinical assessment and in the context of an integral medical treatment. This association recommends a close surveillance of the use of these drugs, specially when formulated as non-propietary prescriptions
Buscar en Google
Colección:
01-internacional
Base de datos:
LILACS
Asunto principal:
Depresores del Apetito
/
Obesidad
Límite:
Humans
Idioma:
Es
Revista:
Rev. méd. Chile
Asunto de la revista:
MEDICINA
Año:
1995
Tipo del documento:
Article